Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 08/24 10:01:36 pm
118.71 USD   -0.61%
08/22 FOR U.S. MEDIA : Janssen Announces 25 Presentations at Upcoming ESC..
08/21 JOHNSON & JOHNS : With B.good, healthy eating comes to King of Pruss..
08/21 JOHNSON & JOHNS : Going from big pharma to farm-fresh
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Biomet To Settle With DOJ, SEC On Bribery Charges For $22.7Mln

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/26/2012 | 05:50pm CEST

Medical-device company Biomet Inc. has agreed to pay about $22.7 million to settle civil and criminal charges stemming from allegations the company's units and agents bribed public doctors in Argentina, Brazil and China for nearly a decade to win business, the Department of Justice and the Securities and Exchange Commission said Monday.

The agencies allege that Biomet and its four units paid bribes from 2000 to August 2008, and employees and managers at all levels of the parent company and the units were involved, along with distributors. Biomet's compliance and internal audit functions failed to stop the payments to doctors even after learning about the illegal practices, the agencies alleged.

A Biomet representative wasn't immediately available for comment.

Biomet agreed to pay a $17.3 million criminal penalty for allegedly violating the Foreign Corrupt Practices Act. In its Justice Department agreement, it is required to implement rigorous internal controls, cooperate fully with the Justice Department and retain a compliance monitor for 18 months. Additionally, the company will pay $5.4 million in disgorgement of profits and prejudgment interest, as part of its separate SEC settlement.

Biomet, a privately held company that sells products used by orthopedic surgeons, is the third medical device firm to enter into a settlement with government agencies as part of the SEC and Justice Department's ongoing global investigation into medical-device companies allegedly bribing publicly employed physicians. Previously, Johnson & Johnson (>> Johnson & Johnson) and Smith & Nephew PLC (SNN, SN.LN) agreed to pay criminal penalties and entered into deferred prosecution agreements related to similar investigations, the Justice Department said.

In January, Biomet said its fiscal second-quarter loss widened as a drop in spine and bone-healing sales as well as higher costs masked the company's revenue growth.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Johnson & Johnson
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/22 FOR U.S. MEDIA ONLY : Janssen Announces 25 Presentations at Upcoming ESC Congres..
08/21 JOHNSON & JOHNSON : With B.good, healthy eating comes to King of Prussia
08/21 JOHNSON & JOHNSON : Going from big pharma to farm-fresh
08/19 JOHNSON & JOHNSON : Diabetes Selfcare Demands Retail, Health Care Collaboration ..
08/19 JOHNSON & JOHNSON : ex-dividend day
08/18 JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA to Expand Indication..
08/18 JOHNSON & JOHNSON : Frost & Sullivan MindXChange Reveals How Organizations Can L..
08/18 JOHNSON & JOHNSON : Announces Ruling Related to REMICADE in the District of Mass..
08/18 JOHNSON & JOHNSON : Patanjali enters babycare segment
08/17 JOHNSON & JOHNSON : Patent for J&J's Remicade invalidated, cheaper version looms
More news
Sector news : Pharmaceuticals - NEC
08/24DJPFIZER : Buys Part of AstraZeneca's Antibiotics Business -- 2nd Update
08/24DJASTRAZENECA : Sells Part of its Antibiotics Business to Pfizer -- Update
08/24DJPfizer Buys Part of AstraZeneca's Antibiotics Business
08/24DJASTRAZENECA : Sells Part of Antibiotics Business to Pfizer for Up to $1.575 Bill..
08/23DJU.S. Lawmakers Plan Hearing Over Wave of Agriculture Mergers
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/24 Merck Offers Value, Yield, And Reliable Dividends
08/24 How Dividend Growth Investors Can Prosper Even If Interest Rates Increase
08/24 Build A Profitable Dividend Growth Investing Portfolio From Scratch (Podcast ..
08/24 PFIZER-MEDIVATION DEAL : Good Or Bad For Shareholders?
08/24 When Can Portola's Drug Be Approved, And How Much Does It Matter?
Advertisement
Financials ($)
Sales 2016 72 068 M
EBIT 2016 21 808 M
Net income 2016 16 515 M
Finance 2016 13 074 M
Yield 2016 2,62%
P/E ratio 2016 20,33
P/E ratio 2017 17,96
EV / Sales 2016 4,35x
EV / Sales 2017 4,06x
Capitalization 326 773 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 127 $
Spread / Average Target 6,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.57%326 773
ROCHE HOLDING LTD.-11.47%219 257
NOVARTIS AG-9.45%214 603
PFIZER INC.7.87%212 844
MERCK & CO., INC.18.76%175 812
GLAXOSMITHKLINE PLC21.19%106 755
More Results